RxDoctor Payments Data

Shanique Thompson, NP

Psychiatric/Mental Health · Clearwater, FLNPI 1609582980

Payments from drug & device makers

$3,935in general payments, 2019–2025

Across 249 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$813
  • AbbVie$718
  • Teva Pharmaceuticals USA, Inc.$701
  • Johnson & Johnson$528
  • Alkermes, Inc.$402
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$231
  • plus $543 from 9 others

What the payments were for

  • Food & beverage$3,82697%
  • Education$1093%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,935 in reported general payments places this provider in the 85th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$1,923
Medicare patients
12
Services billed
21

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl18$24,877
Aripiprazole15$676
Quetiapine Fumarate19$612
Buspirone Hcl25$508
Hydroxyzine Pamoate37$426
Olanzapine17$333
Gabapentin22$284
Divalproex Sodium20$258
Trazodone Hcl38$230
Mirtazapine13$228
Lamotrigine14$207
Clonazepam21$183
Risperidone11$155
Bupropion XlBupropion Hcl15$153
Sertraline Hcl20$77

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$718$24,87718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →